← Eichor
Study identifier: NCT06087627 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine

Condition: Prurigo Nodularis  ·  Sponsor: Sanofi

PhaseN/A
Planned participants150
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Prurigo nodularis (PN) is a skin disease characterized by the presence of single to multiple symmetrically distributed, intensively itching nodules. The main symptom is uncontrollable itching leading to prolonged, repetitive, and uncontrollable rubbing, scratching which in turn causes injuries to the skin. In recent years, number of studies evaluating PN, the affected population and the disease burden has increased but PN remains still understudied. This non-interventional study is intended to describe the long-term effectiveness of dupilumab (Dupixent®) in participants aged 18 years or older and suffering from moderate-to-severe PN who receive dupilumab for PN treatment in a real-world setting in Germany according to the prescribing information (Summary of Product Characteristics \[SmPC\]). The decision to initiate dupilumab treatment is made by the treating physician and participant according to the participant's medical need and to the standard of best medical practice. This decision is made independently and before data inclusion in this non-interventional study.

This description comes directly from the study's public registry record.

Talk to the study team

Trial Transparency email recommended (Toll free for US & Canada)  ·  800-633-1610  ·  Contact-US@sanofi.com

Always discuss trial participation with your own doctor first.

Locations (11)

Investigational Site Number: 013Adernach, GermanyRecruiting
Investigational site number: 001Berlin, GermanyRecruiting
Investigational Site Number: 002Berlin, GermanyRecruiting
Investigational Site Number: 023Chemnitz, GermanyRecruiting
Investigational Site Number: 005Düren, GermanyRecruiting
Investigational Site Number: 004Düsseldorf, GermanyRecruiting
Investigational Site Number: 007Hamburg, GermanyRecruiting
Investigational Site Number: 016Leipzig, GermanyRecruiting
Investigational Site Number: 031Mainz, GermanyRecruiting
Investigational Site Number: 022Potsdam, GermanyRecruiting
Investigational Site Number: 024Potsdam, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06087627